Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Original Article
T.D. Shanafelt, X.V. Wang, N.E. Kay, C.A. Hanson, S. O’Brien, J. Barrientos, D.F. Jelinek, E. Braggio, J.F. Leis, C.C. Zhang, S.E. Coutre, P.M. Barr, A.F. Cashen, A.R. Mato, A.K. Singh, M.P. Mullane, R.F. Little, H. Erba, R.M. Stone, M. Litzow, and M. Tallman
N Engl J Med 2019;381:432-443
Course summary
Available credit:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course opens:
07/31/2019
Course expires:
08/01/2021
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Sunday, August 1, 2021 - 11:59pm.

Facebook
X
LinkedIn
Forward